What is the NCCN recommended monitoring schedule for active surveillance in patients with pT1a renal cell carcinoma (RCC)?

Updated: May 21, 2019
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print
Answer

In patients with a clinically localized renal neoplasm who have chosen active surveillance, the American Urological Association (AUA) [73]  and the National Comprehensive Cancer Network (NCCN) [20]  recommend similar follow-up measures. The NCCN monitoring schedule for active surveillance in patients with pT1a disease is as follows [20] :

  • History and physical examination every 6 mo for 2 y, then annually up to 5 y after diagnosis
  • Comprehensive metabolic panel and other tests as indicated every 6 mo for first 2 y, then annually up to 5 y after diagnosis
  • Abdominal CT or MRI within 6 mo of surveillance initiation, then CT, MRI, or US at least annually
  • Chest x-ray or CT annually to assess for pulmonary metastases, if biopsy positive for RCC
  • Pelvic CT or MRI, as clinically indicated
  • CT or MRI of head or MRI of spine, as clinically indicated
  • Bone scan, as clinically indicated

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!